AZD4017: Clinical Trials

3 trials of AZD4017, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3

Follow AZD4017: new trials by email Literature Review of AZD4017 trials Research Report on AZD4017

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Glucocorticoids and Skin Healing in Diabetes (GC-SHealD)
AZD4017, Placebo - Diabetes Mellitus, Type 2
Phase 2CompletedUniversity of Leeds282018-04-102019-03-22
Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.
AZD4017, Placebo - Idiopathic Intracranial Hypertension
Phase 2CompletedUniversity of Birmingham312014-04-252021-10-27
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
AZD4017, Placebo - Raised Intraocular Pressure
Phase 2CompletedAstraZeneca502010-12-012014-02-14

Conditions studied

Blindness (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Headache (1)  ·  Intracranial Hypertension (1)  ·  Obesity (1)  ·  Ocular Hypertension (1)  ·  Papilledema (1)  ·  Pseudotumor Cerebri (1)  ·  Tinnitus (1)

Sponsors

AstraZeneca (1)  ·  University of Birmingham (1)  ·  University of Leeds (1)

Countries

United Kingdom (3)  ·  Sweden (1)  ·  United States (1)

Top investigators

Alexandra Sinclair, MbChb PhD (1)  ·  Heather Bryson, PhD (1)  ·  Tony Ho, MD (1)

Results publications

PMID 28923789, PMID 33098644, PMID 36240084, PMID 37740611